Clinical trials using stem cells have shown promising early results as cellular therapies in regenerative medicine, as well as in potential anti-cancer applications. Read more about Dr. Achal Singh Achrol’s neurosurgery clinical trials program and this leading-edge technology.
Nanotechnology is a compelling new drug delivery method in oncology where nanoparticles are engineered to target therapeutics to kill cancer. Find out more in Dr. Venkata Yenugonda’s review article in the March 2019 issue International Journal of Nanomedicine.
Dementia Deaths Have More Than Doubled—But How Exactly Can It Kill You? Doctors explain the deadly complications that can arise from this cluster of conditions.
The spine plays multiple essential roles in the body and anyone who has had a back issue can attest to how debilitating the pain can be. A new comprehensive specialty spinal care center opens with PNI-South Bay, at Little Company of Mary Medical Center in Torrance, California.
Disorders of nerves and muscles can develop in the arms and legs over time resulting in more falls while walking and hand weakness. Sensation is diminished and physical, cognitive and emotional health often suffers. Find out more about neuromuscular disorders.
The neurosciences clinical trials team is pleased to announce two new clinical trials in Overactive bladder and Alzheimer’s disease. Find out more.
Going from aerospace engineering to eye surgery, Dr. Howard R. Krauss is a surgical neuro-ophthalmologist. Hear him explain what that is and how this specialized skill can help patients with tumors affecting the eye and vision.
Participants go “Over the Edge for Brain Cancer” and rappel down San Diego’s tallest waterfront building to bring new awareness to brain cancer research.
Electrical stimulation therapy may have a big impact on brain health and recovery in patients with mood disorders, dementia and neurodegenerative disorders.
Pacific Neuroscience Institute, the leading enrollment site for the MDNA55 clinical trial for Glioblastoma, is still open and enrolling eligible patients. This innovative phase 2 study is for the minimally invasive convection-enhanced delivery (CED) of a new bioengineered targeted therapeutic, MDNA55, in adults with recurrent or progressive glioblastoma. Read more.